Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7705960 | 1.00 | MEN1 (0.41) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL362466 | 0.88 | ALOX15 (0.42) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL16357610 | 0.88 | ALDH1A1 (0.50) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL18954258 | 0.87 | ALOX15 (0.34) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL3870295 | 0.83 | LMNA (0.53) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL156683 | 0.83 | — | — | |
| SCHEMBL11651471 | 0.82 | TSHR (0.42) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL3897447 | 0.81 | TSHR (0.46) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL13839555 | 0.81 | TSHR (0.46) | MEN1KMT2AALOX15CYP3A4ALDH1A1 | |
| SCHEMBL29011335 | 0.80 | TSHR (0.41) | MEN1KMT2AALOX15CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931324-B1 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RES FOUND (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-1931324-B1 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RES FOUND (US) | 2015-01-28 | — | — | EP | disclosed |
| US-7534777-B2 | Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534777-B2 | Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534777-B2 | Des-C,D analogs of 1α,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1931324-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| WO-2007028000-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028000-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-0983221-B1 | CYCLOHEXANEDIOL DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-04-03 | — | — | EP | disclosed |
| EP-0983221-A1 | CYCLOHEXANEDIOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-08 | — | — | EP | disclosed |
| US-5969190-A | TREATING HYPERPROLIFERATIVE SKIN DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1998052894-A1 | CYCLOHEXANEDIOL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | CYP24A1, VDR, CYP2R1 | MEN1 279/4885KMT2A 4855/4885ALOX15 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.